secukinumab
novartis
['secukinumab']
patients with axial spondyloarthrtitis who have not previously been treated with a biologic are much more likely to have a clinical response from secukinumab. #acr2022 
Clinical News for Connected Physicians. Everything you need to enhance your clinical approach to improving patient care.